Fat jab users will go to dodgy online sellers if Mounjaro rollout is botched by NHS, drug bosses warn
Just eight of 42 health service boards offer the weight-loss injection after a launch in June, stats show.
Under current plans it will take 12 years for all the 3.4 million eligible people to get it.
Dr Emily Pegg of Lilly, which makes Mounjaro, told The Sun: 'We worry more people will be forced to seek it from potentially illegitimate and dangerous sources.'
Dr Pegg warned social media sellers and dodgy online pharmacies posed a threat.
She said: 'This is a prescription-only medication that comes with many rules and regulations.
"A lot of people who are buying illicit medicines may not realise the potential danger.'
Mounjaro is available on the NHS only to the most obese patients.
More than 1.5 million Britons are thought to be taking weight-loss drugs, mostly on private prescription.
Henry Gregg, from the National Pharmacy Association, said the NHS rollout was proceeding very slowly.
He added: 'There are concerning reports of clinically ineligible patients trying to source medication from unregulated sources.
'This could pose a serious risk to a patients' health.'
I've lost nearly 6 stone in 9 months on fat jabs - trolls call me 'lazy' & say it's the 'easy way out' but I don't care
A Department of Health spokesman said: 'We expect NHS boards to be making these drugs available.
"We are determined to bring revolutionary modern treatments to everyone who needs them.'
1
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
26 minutes ago
- The Sun
Prince Harry criticised over row that risks damaging his charity's reputation
PRINCE Harry was blasted last night for letting a boardroom battle damage his charity Sentebale. A watchdog said the public row risked undermining trust in good causes generally. 2 The Charity Commission said chances were missed to settle differences at Sentebale, set up by Harry and Lesotho's Prince Seeiso in 2006 for young people and kids living with HIV and Aids. It launched a probe when they stood down as patrons in support of trustees who quit in a dispute with Dr Sophie Chandauka over a fundraising strategy. Board of trustees chair Dr Chandauka said the 'toxicity' of Harry's brand since his move to live in the US had seen a drop in donors. She accused the Duke of Sussex, 40, of involvement in a 'cover-up' of a probe into bullying and harassment. Last night, she said the 'adverse media campaign' launched by those who resigned 'caused incalculable damage' to the charity. The Times reported a source close to Harry blasted the report and said the prince was 'devastated the chair had been allowed to succeed with a hostile takeover'. His spokesman said those who rely on Sentebale would bear the 'consequences of her actions'. The Charity Commission said the public airing of the row harmed Sentebale's reputation and risked overshadowing its achievements. The regulator, which cannot investigate individual allegations of bullying, found no evidence of systemic bullying or harassment, including misogyny or misogynoir at the charity but acknowledged 'the strong perception of ill treatment' felt by some involved. David Holdsworth, chief executive of the Charity Commission, said: 'Passion for a cause is the bedrock of volunteering and charity, delivering positive impact for millions of people here at home and abroad every day. Harry QUITTING his own charity is utterly humiliating - misogyny row will hurt him deeply 'However, in the rare cases when things go wrong, it is often because that very passion has become a weakness rather than a strength. 'Sentebale's problems played out in the public eye, enabling a damaging dispute to harm the charity's reputation, risk overshadowing its many achievements, and jeopardising the charity's ability to deliver for the very beneficiaries it was created to serve.' 2
Scottish Sun
an hour ago
- Scottish Sun
New cancer treatment that slashes risk of death by a quarter gives fresh hope to thousands in ‘major step forward'
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WOMEN with advanced womb cancer have been given fresh hope with the approval of a new drug. The treatment, which can slash the risk of death by 26 per cent, was given the green light for widespread NHS use. Sign up for Scottish Sun newsletter Sign up 1 Pembrolizumab, also known as Keytruda, has been licensed to treat advanced or recurring endometrial cancer Credit: Alamy Just 15 per cent of women live for five years if they have been diagnosed with advanced endometrial cancer - a cancer which usually starts in the lining of the womb. The National Institute for Health and Care Excellence (NICE) has now made a treatment, called pembrolizumab, available on the NHS in England for people with advanced or recurring endometrial cancer. The drug can slow down cancer growth and improve survival odds, health officials said. NICE estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment marks a "major step forward" in treatment for women with this type of cancer. Pembrolizumab, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug. This is a type of treatment that mobilises the body's own immune system to fight cancer. The drug is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given to patients for up to two years. According to NICE, clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The drug combo can also slow down cancer progression, the regulator added. Cervical cancer warning signs you should NEVER ignore, with Doctor Philippa Kaye Helen Knight, director of medicines evaluation at NICE, said: "For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. "It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer." Around 9,700 women are diagnosed with endometrial cancer - also known as womb or uterine cancer - each year, making it the most common gynaecological cancer in the UK, according to NICE. The disease is most common in older women. Womb cancer symptoms Cancer of the womb is often called uterine or endometrial cancer. Symptoms include: Bleeding after the menopause Bleeding that is unusually heavy or persistent between periods Abnormal vaginal discharge (this might be pink) Anaemia High platelet count High blood sugar levels Stomach pain Swollen tummy Bloating Change in bowel or bladder habits A new cough Being overweight or obese is one of the biggest risks of womb cancer, according to Cancer Research UK. Other risk factors include age (most women diagnosed are aged 75 to 79) as well as being on hormone replacement therapy (HRT) and having diabetes or polycystic ovary syndrome (PCOS). Having too much of the hormone oestrogen is thought to raise your risk of womb cancer, according to the Eve Appeal. Fat cells in the body store oestrogen, even after the menopause and obesity has been linked to womb cancer because of its effect on oestrogen levels. It's not always possible to prevent womb cancer, but some things are thought to reduce your risk, like maintaining a healthy weight. Source: Cancer Research UK Its most common symptom is abnormal bleeding from the vagina, that is heavier than usual and occurs between periods or after menopause. It can also cause pink-tinged vaginal discharge, as well abdominal pain, bloating and a change in bladder or bowel habits. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: "Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. "It is great news that this new treatment has been approved. "It will offer hope, a better quality of life and improve outcomes for those affected."
The Independent
an hour ago
- The Independent
Nationwide leads new calls for change to protect domestic abuse survivors
Nationwide Building Society has partnered with Refuge, the UK's largest domestic abuse charity, in a bid to both bring about change and help protect survivors of abuse. The partnership is aiming to extend existing support for victims, as well as remove barriers which can prevent survivors from taking back control of their lives. A key part of the reform being asked for is for the Individual Insolvency Register (IIR) to be made private, protecting survivors' details, while also removing the £308 fee currently due. 'Nationwide and Refuge have signed Money Wellness's campaign to get the g overnment to make the IIR private – protecting the addresses of survivors who have become insolvent through bankruptcy, for example,' a statement read. 'Domestic abuse survivors often struggle to pay for this protection order because abusers typically exercise full financial control, leaving survivors with little or no personal funds. This comes in addition to the increased risk survivors face when having to list their details on the register.' Earlier this year, Nationwide and Refuge partnered with The Independent on the Brick by Brick campaign, with a second safe haven built for women fleeing domestic abuse, completed in July. Office for National Statistics records show 2.3 million adults in England and Wales experienced domestic abuse across 2023-24, including 1.6 million women. Women are more than twice as likely to be affected. In addition, specialist support staff will be able to refer people to Refuge via telephone, while Nationwide – as well as other financial institutions– offer safe spaces within branches where at-risk individuals can call family or sort through financial issues. Staff are also trained to help spot signs of domestic abuse. Emma Pickering, head of technology-facilitated abuse at Refuge, said: 'One in four women will experience domestic abuse in their lifetime, and cases are continuing to grow in both quantity and complexity. Thanks to Nationwide Building Society, Refuge will be able to expand its support for survivors of abuse. 'Our partnership has never been more needed. With Nationwide's support, Refuge's expert team will empower survivors with practical advice and emotional support, helping them to rebuild their lives. No survivor should have to navigate domestic abuse alone, and Nationwide's commitment means we will be able to ensure even more survivors receive the support they deserve.' It's not too late to support Refuge and to help more survivors find their freedom. Donations will be spent on Refuge's lifesaving work housing survivors of domestic abuse.
